Celldex Therapeutics Inc
Atvērts
SektorsVeselības aprūpe
32.19 1.71
Pārskats
Akcijas cenas izmaiņa
24h
Min
31.33
Max
32.21
Ienākumi | 2.6M -79M |
|---|---|
Pārdošana | -60K 15K |
EPS | -1.18 |
Peļņas marža | -524,566.667 |
Darbinieki | 198 |
EBITDA | -3M -84M |
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +59.09% upside |
Nākamie ieņēmumi | 2026. g. 5. aug. |
|---|
Tirgus kapitalizācija | -330M 2.2B |
|---|---|
Iepriekšējā atvēršanas cena | 30.48 |
Iepriekšējā slēgšanas cena | 32.19 |
Ziņu noskaņojums
By Acuity
50%
50%
162 / 342 Rangs Healthcare
Celldex Therapeutics Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
